Deciphering Preserved Autonomic Function After Multiple Sclerosis
Mayo Clinic · NCT07012135
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 13
- US sites recruiting
- 1
- Study start
- September 17, 2025
- Record last updated
- May 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.
Being studied: Tests of sympathetic inhibition; Tests of sympathetic activation; Testing of autonomic dysreflexia
Conditions: Multiple Sclerosis; Control Subjects; Autonomic Dysreflexia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18-50 years old
- clinically confirmed diagnosis of multiple sclerosis -OR- uninjured control
Exclusion Criteria
- symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment)
- women who are pregnant or lactating
- having a body mass index (BMI) ≥ 35 kg/m2
- taking or being administered a medication known to potentially have adverse interactions with phenylephrine
- in the judgement of the principal investigator or clinical collaborator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
Recruiting US locations
Mayo Clinic
Rochester, MN 55902
Site contact: Erin Lund · 507-284-9298 · lund.erin@mayo.edu
Study contacts (from the official record)
- Erin Lund · 507-284-9298 · lund.erin@mayo.edu
Similar studies in Minnesota
All neurology studies in Minnesota →- RecruitingHealthy volunteersPhase 1
Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults
Alcamena Stem Cell Therapeutics
- Location
- Saint Paul, MN
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1
Microelectrode Recordings From the Vagus Nerve in Awake Humans
University of Minnesota
- Location
- Minneapolis, MN
- Eligibility basics
- Ages 18–40
- RecruitingHealthy volunteersEarly Phase 1
Stimulating After Recovery From Traumatic Brain Injury
University of Minnesota
- Location
- Minneapolis, MN
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Rochester, MN + 9 other US sites
- Eligibility basics
- Ages 6 mo–17